Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de Evidencia del Mundo Real TARSILA (TARSILA)

2 de noviembre de 2026 actualizado por: Maicon Falavigna, Inova Medical

Efectividad en el mundo real de la vacunación materna con RSVpreF contra la enfermedad respiratoria aguda asociada al RSV en lactantes en Brasil (Estudio TARSILA): un estudio multicéntrico, prospectivo, de casos y controles con prueba negativa

The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.

Descripción general del estudio

Descripción detallada

Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.

Tipo de estudio

De observación

Inscripción (Estimado)

5000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Paraná
      • Cascavel, Paraná, Brasil, 85818-130
        • Reclutamiento
        • Unidade de Pronto Atendimento Veneza
        • Contacto:
      • Curitiba, Paraná, Brasil, 80060-900
        • Reclutamiento
        • Complexo do Hospital de Clínicas da Universidade Federal do Paraná
        • Contacto:
        • Investigador principal:
          • Cristina de Oliveira Rodrigues
      • Curitiba, Paraná, Brasil, 80240-031
        • Reclutamiento
        • Hospital Infantil Pequeno Príncipe
        • Contacto:
        • Investigador principal:
          • Heloisa Ihle Garcia Giamberardino
      • Marechal Cândido Rondon, Paraná, Brasil, 85960-000
        • Reclutamiento
        • Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
        • Contacto:
      • Palotina, Paraná, Brasil, 85950-000
        • Reclutamiento
        • Unidade de Saúde Central de Palotina
        • Contacto:
      • Toledo, Paraná, Brasil, 85902-480
        • Reclutamiento
        • Unidade de Pronto Atendimento II de Toledo
        • Contacto:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 91350-200
        • Reclutamiento
        • Hospital Nossa Senhora da Conceição
        • Contacto:
        • Investigador principal:
          • Fernanda H Varela
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • Reclutamiento
        • Hospital de Clínicas de Porto Alegre
        • Contacto:
        • Investigador principal:
          • Ricardo Becker Feijó

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

No mayor que 11 meses (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Infants with acute respiratory illness (ARI)

Descripción

Tarsila Inpatient Study

Inclusion Criteria

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Maternal or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Infant previously enrolled in this study.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.

Tarsila Outpatient Study

Inclusion Criteria:

  • Infant born in Brazil.
  • Mother resident in Brazil during the related pregnancy.
  • Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
  • Infant ≤360 days of age at time of RSV specimen collection.
  • Infant born at ≥37 weeks of gestational age.
  • Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Exclusion Criteria:

  • Mother or infant receipt of any other licensed or investigational RSV preventive product.
  • Infant receipt of blood transfusion or other blood products containing antibodies since birth.
  • Lack of informed consent from the mother or the infant's legal guardian.
  • Absent or inconclusive RT-qPCR result for RSV.
  • Birth to a mother whose RSVpreF vaccination status could not be confirmed.
  • Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_CONTROL
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Cases

Infants with a positive respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

Controls

Infants with a negative respiratory syncytial virus result on a nasal swab specimen

For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing).

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
Periodo de tiempo: Occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).

Occurring ≤180 days after birth.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) .

Hospitalization occurring ≤180 days after birth
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:

  • Gestational age at RSVpreF vaccination.
  • Time from RSVpreF vaccination to birth.
  • Time intervals of infant age at illness.
Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
Periodo de tiempo: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness.

ARI occurring ≤180 days after birth

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization

RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization.

Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) .

Hospitalization occurring ≤180 days after birth
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.

RT-qPCR-confirmed RSV-positive LRTD in-hospital death.

Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
Hospitalization occurring ≤180 days after birth
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness.

Hospitalization occurring ≤360 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization

Hospitalization occurring ≤180 days after birth
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI hospitalization.

Hospitalization occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
Periodo de tiempo: Hospitalization occurring ≤180 days after birth

RT-qPCR-confirmed HMPV-positive LRTD hospitalization

Hospitalization occurring ≤180 days after birth
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
Periodo de tiempo: ARI occurring ≤180 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by:

  • RSV subtype (RSV-A, RSV-B).
  • Human milk feeding status (e.g., breastfeeding).
  • RSVpreF administration with other vaccines received during pregnancy.
  • RSVpreF vaccination status in a previous pregnancy.
ARI occurring ≤180 days after birth
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
Periodo de tiempo: ARI occurring ≤360 days after birth

RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness.

ARI occurring ≤360 days after birth
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
Periodo de tiempo: LRTD occurring ≤180 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤180 days after birth.
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
Periodo de tiempo: LRTD occurring ≤360 days after birth.

RT-qPCR-confirmed RSV-positive LRTD.

LRTD occurring ≤360 days after birth.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Maicon Falavigna, Inova Medical

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de abril de 2026

Finalización primaria (Estimado)

30 de septiembre de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

20 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

25 de febrero de 2026

Publicado por primera vez (Actual)

3 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir